8-K: Current report filing
Published on April 21, 2003
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): March 14, 2003
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| Virginia (State or Other Jurisdiction of Incorporation) |
001-13467 (Commission File Number) |
56-1641133 (I.R.S. Employer Identification No.) |
| 601 Biotech Drive Richmond, Virginia 23235 (Address of Principal Executive Offices) |
Registrants telephone number, including area code: (804) 648-3820
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On April 23, 2002, the registrant engaged Segerdahl & Company, Inc. (Segerdahl) to provide certain investment banking services. This agreement was to terminate on April 11, 2003. On March 14, 2003, the Company extended such engagement to October 31, 2003.
2
Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly ceased this report to be signed on its behalf by the undersigned thereunto duly authorized.
| COMMONWEALTH BIOTECHNOLOGIES, INC |
||||||||
| Dated: April 21, 2003 |
By: |
/s/ ROBERT B. HARRIS, PH.D. |
||||||
| Robert B. Harris, Ph.D. President and Chief Executive Officer |
||||||||
3